Moderna Stock Pushed Higher Despite Lower Earnings Forecast: MRNA Technical Analysis
Moderna disclosed product sales of $6.7 billion in 2023, exceeding their initial forecast of at least $6 billion but indicating a decline of 63.6% compared to 2022.
Moderna Inc (NASDAQ: MRNA) Stock: Traders Looking for the Best Biotech Stock to Buy Should Look Here
Moderna stock is trading at a steep discount to its all-time high. Take a look at the MRNA stock forecast and short interest to see what the future might hold.
Discover the Top 7 Best Biotech Stocks to buy for Traders
Get to know the top 7 best biotech stocks to buy, including biotech companies overview and biotech stocks trading strategies.